Summary. The phosphodiesterase (PDE) 5 inhibitor sildenafil has been shown to display psychotropic actions in humans and animals, and has been used for the treatment of antidepressant-associated erectile dysfunction. However, its effects on the neurobiology of depression are unknown. Nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) inhibition is antidepressant in animals, and increasing cGMP with sildenafil is anxiogenic in rodents. Substantial cholinergic-nitrergic interaction exists in the brain, while sildenafil shows modulatory actions on cholinergic transmission. Depression is also associated with increased cholinergic drive. Here we report that sildenafil increases muscarinic acetylcholine receptor (mAChR) signaling in human neuroblastoma cells. We also show that fluoxetine (20 mg=kg=day Â 7 days), as well as a combination of sildenafil (10 mg= kg=day Â 7 days) plus the antimuscarinic atropine (1 mg=kg=day Â 7 days) demonstrates significant, comparable antidepressant-like effects in the rat forced swim test (FST) and also reduces cortical b-adrenergic receptor (b-AR) density, while sildenafil or atropine alone did not. Importantly, sildenafil did not modify fluoxetine's response. Sildenafil thus demonstrates antidepressant-like effects but only after central muscarinic receptor blockade, providing evidence for cholinergic-nitrergic interactions in the neurobiology of depression.
Introduction
Although antidepressants directly target the synaptic regulation of monoamine neurotransmission (Manji et al. 2003) , post-synaptic transcriptional events mediating neuroplasticity are pivotal in this response (Manji et al. 2003) . Recently, the role of the nitric oxide (NO) soluble guanylate cyclase-cyclic guanosine monophosphate (cGMP) pathway in the neurobiology of depression has gained interest (Paul and Skolnick 2003) .
Selective neuronal NO synthase (NOS) inhibitors (Harkin et al. 2004 ) bolster the actions of typical antidepressants, while diverse antidepressants, including serotonin reuptake inhibitors (SRIs), inhibit hippocampal NOS activity Harvey et al. 2006) . Finally, NOS inhibitors (Harkin et al. 1999) as well as soluble guanylate cyclase inhibitors (Heiberg et al. 2002) are antidepressant in animal models. Importantly, altered NO processing has been described in patients with depression (Bernstein et al. 1998; Chrapko et al. 2006) .
Sildenafil bolsters cGMP through selective inhibition of cGMP phosphodiesterase type 5 (PDE5), an enzyme dominant in rodent olfactory bulb, cortical layers, and hippocampus, albeit markedly less than that of other cGMP-PDE isoforms (van Staveren et al. 2003) . Recent pharmacogenetic studies suggests that alteration of cGMP-related PDEs may represent a novel strategy for the treatment of depression (Wong et al. 2006) . However, sildenafil is anxiogenic in animal models Kurt et al. 2004) , inferring that raised levels of cGMP may represent an as yet undisclosed protagonist in the neuropathology of depression. That sildenafil is effectively used to treat male erectile impotence in depressed patients without evidence that it worsens depression or counters antidepressant action (Tignol et al. 2004) , presents with an interesting conundrum.
Animal studies have provided evidence of a psychotropic role for cGMP, for example in the mood stabilizing actions of lithium (Harvey et al. 1990 (Harvey et al. , 1994 . However, the effects of lithium on cGMP appear to involve enhanced cholinergic drive (Harvey et al. 1990 ). Interestingly, sildenafil too bolsters cholinergic responses in the brain (Devan et al. 2004; Patil et al. 2004; ) . Janowsky et al. (1972) first proposed that heightened cholinergic activity may mediate major depression. The cholinergic system is activated during stress (Kaufer et al. 1998) , while the Flinders Line Sensitive (FLS) rat, a genetic rodent model of depression, presents with increased stress sensitivity and an over-activity of the cholinergic system (Daws and Overstreet 1999) . Of particular interest is that the antimuscarinic, scopolamine, evokes a rapid, robust antidepressant response in treatment resistant depression (Furey and Drevets 2006) .
We sought to determine the cholinotropic effects of sildenafil on muscarinic acetylcholine receptor (mAChR) function using a cultured human neuronal cell line. Thereafter, we investigated the antidepressant-like properties of sildenafil in rats after chronic dosing using the forced swim test (FST), together with cortical b-adrenoceptor (b-AR) density, a putative neuropharmacological correlate of antidepressant action. We then investigated the ability of sildenafil to modify the actions of the known antidepressant, fluoxetine, in the FST and on cortical bARs, and whether any actions of sildenafil on the above parameters could be modified by concomitant administration of the mAChR antagonist, atropine.
Material and methods

Drugs, chemicals, radioligands and culture media
Sildenafil was a kind gift from Pfizer Global Research and Development (Kent, United Kingdom). Fluoxetine hydrochloride was a generous gift from Aspen (Port Elizabeth, South Africa). Atropine was obtained from Merck (Darmstadt, Germany).
Formic acid was obtained from Saarchem-Holpro Analytic (Krugersdorp, Gauteng, South Africa). Acetyl-b-methylcholine chloride (methacholine chloride), atropine sulfate, LiCl, propranolol hydrochloride, Bradford reagent, ethylenediaminetetraacetic acid (EDTA), ascorbic acid and fractioned bovine serum albumin (BSA) were obtained from Sigma Chemical (St. Louis, MO, U.S.A.). 2-Amino-2-hydroxymethyl-propan-1,3,-diol (Tris) was obtained from Acros (Geel, Belgium). Tris-HCl and MgCl 2 were obtained from USB (Cleveland, U.S.A.). Filter count LSC-cocktail was obtained from PerkinElmer Life and Analytical Sciences (Boston, U.S.A.). Serotonin creatinine sulphate was obtained from BDH Chemicals (Poole, England).
myo-[2- Ham's F-12 medium, minimum essential medium (Earle's base) (EMEM), Dulbecco's modified Eagle's medium (DMEM): Ham's F-12 (1:1 ratio mixture) was obtained from Bio Whittaker (Walkersville, U.S.A.). Trypsin-versine, bovine serum albumin (BSA) and DMEM were obtained from Highveld Biological (Johannesburg, South Africa). Foetal bovine serum (FBS) and penicillin-streptomycin mixture were obtained from Gibco TM Invitrogen Life Technologies (California, U.S.A.).
Cell line
In this study we used a human neuroblastoma (SH-SY5Y) cell line, obtained from Highveld Biological (Lyndhurst, Gauteng, South Africa), originally from the American Type Culture Collection (U.S.A.). SH-SY5Y cells endogenously express predominantly M 3 -mAChRs (Slowiejko et al. 1996) , with some evidence for M 1 -and M 2 -mAChRs (Kukkonen et al. 1992 Seeding and drug pre-treatment of cultured cells for experiments SH-SY5Y cells were seeded at a density of approximately 10 6 cells=well in 24-well plates and maintained for at least 5 h to allow adequate cell attachment. Thereafter the drug pre-treatments were initiated by rinsing the cells twice with EMEM and incubating them for 24 h with 0, 100 or 450 nM sildenafil in serum-free EMEM, supplemented with 0.1 mM myo-inositol. It has been shown previously that 0.1 mM myo-inositol is necessary for optimal for normal muscarinic acetylcholine receptor function (Brink et al. 2004) . The pre-treatment concentrations for sildenafil were chosen as 100 and 450 nM, obtained from reported therapeutic plasma concentrations (Thummel et al. 2006) . After the 24-h pre-treatment, cells were rinsed twice with EMEM, followed by the appropriate preparations for the functional [ ]-inositol phosphates (IP x ) accumulation was determined in whole SH-SY5Y cells in 24-well plates as described before (Brink et al. 2004; Bodenstein et al. 2005) . Briefly, cells were labelled by adding 1 mCi per well myo-[2-3 H]inositol in inositol-free medium (EMEM, Earle's base þ bovine serum albumin) at least 18 h before the assay. Pilot studies have shown that pre-treatment with sildenafil does not influence the total radioactivity incorporated in cells (100 AE 5.0% with control vs. 94 AE 6.1% with 450 nM sildenafil pre-treatment; p ¼ 0.48 -data not shown), indicating that total radioactivity was comparable between treatment groups and that measured [ C and 5% CO 2 the medium was aspirated and the reaction terminated with 1 ml ice-cold 10 mM formic acid and let to stand for at least 90 min at 4 C to lyse the cells. The 
Animals
Male Sprague-Dawley rats weighing AE 200 g on the day of the FST were used in the behavioural experiments. The use of the animals was approved by the Ethical Committee of the North-West University (approval no. 03D08), in accordance with the guidelines of the National Institutes of Health guide for the care and use of laboratory animals. Suffering and discomfort to animals were minimized and the number of animals per group was the minimum needed for assays and meaningful statistical evaluation of 118 C. B. Brink et al. the data. Animals were housed in groups of seven rats in acrylic cages at a controlled temperature (21 C) and humidity (50%). They were maintained on a 12 h light-dark cycle (lights on at 06:00 h) and food and water provided ad libitum. These conditions were maintained constant throughout the experiments.
Drug treatment of animals
Fifteen rats per treatment group were assigned for behavioural and neuroreceptor analyses. These fifteen rats were subdivided into subgroups of five rats per experiment and each experiment carried out in triplicate, days apart, to ensure repeatability. An additional (separate) six rats per treatment group were assigned for the locomotor activity measurements. In this case, two rats per experiment were treated in parallel with the 5 rats per experiment mentioned above, and each experiment carried out in triplicate to ensure repeatability. The animals were weighed each morning where after the dosages were calculated and drug solutions prepared. Fluoxetine (20 mg= kg=day), sildenafil (10 mg=kg=day), atropine (1 mg=kg=day), and the indicated drug combinations, or no drug (control), were dissolved in a 0.9% saline solution containing Tween 80 (3% v=v). All drugs were administrated intra-peritoneally (i.p.) in a volume of 0.5 ml between 08:00 and 09:00 each morning for 7 days. The last dose was given on the morning of the scoring swim trial. The dosage for fluoxetine (Detke and Lucki 1995; Reneric et al. 2001 Reneric et al. , 2002b and atropine (O'Hare et al. 1997) was based on previous studies where similar central effects were required for chronic administration. The dosage of sildenafil was based on previous studies in rats necessary for evoking centrally mediated responses (Ferrari et al. 2002; Prickaerts et al. 2002; Kurt et al. 2004; Harvey et al. 2005) .
Forced swim test (FST)
The FST, a validated and well-established animal model for screening for antidepressant activity over acute (administered between two swim sessions 24 h apart) (Porsolt et al. 1978 ) and chronic drug treatment programs (Porsolt et al. 2000; Reneric et al. 2002a ) was used. In the current study, the pre-conditioning swim was instated on the penultimate day of the designated chronic treatment period, an approach that has been successfully deployed for chronic drug studies (Harvey et al. 2002; Xu et al. 2005) . On the penultimate day of the designated treatment period the animals were placed in the testing room for 60 min to habituate, where after they were placed for 15 min in inescapable Perspex cylinders (diameter 18 cm, height 40 cm) containing 18 cm of clean water and maintained at a constant temperature of 25 C by immersion in a surrounding water bath (157 Â 26 Â 25 cm). The cylinders were separated by opaque screens and the water deep enough to keep the rats from touching the bottom of the cylinder with their hind paws. Following the pre-conditioning swim session the rats were placed in heated cages to dry for 15 min before returning them to their home cages.
On the last day of the treatment period the animals were placed in the testing room for 60 min to habituate, where after they were replaced in the above-described cylinders containing 18 cm of clean water (25 C) for 5 min and their behaviour recorded on video from the side. After the test the rats were placed into heated cages to dry for 15 min.
The scoring of immobility (when no additional activity is observed other than that required to keep the rat's head above the water) was performed by a person blind to the treatment group (Cryan et al. 2002) . The duration (seconds) of immobility during the 5 min swim session was scored separately for each animal.
Locomotor behaviour
On the last day, after the final dose, rats were placed in automised locomotor measurement cages (Accuscan Instruments, Columbus, U.S.A.) for 20 min to habituate, where after the locomotor activity (horizontal activity, defined as number of movements per 10 min) of the animals was digitally recorded and measured for 10 min.
Preparing membranes from rat brain tissue
When the FST was completed, the rats were decapitated and the brains rapidly dissected on ice. The frontal cortex was then snap-frozen and stored at À86
C for a maximum of 3 months. On the day of the radioligand binding study the desired brain regions were removed and allowed to thaw on ice.
Preparing membranes for measurement of b-adrenoceptor density While its role in the therapeutic efficacy of antidepressant drugs is questioned (Suranyi-Cadotte et al. 1985; Baldessarini 2006) , a useful and acknowledged marker for the screening of antidepressant action is a reduction in cortical b-adrenoceptor density, being a collective property of a remarkably wide spectrum of antidepressant drugs (Stahl 1996) . The frontal cortices of five animals were pooled for one experiment and the weight of the tissue recorded. The tissue was homogenized for 10 sec with a Polytron homogenizer in 25 ml ice cold 50 mM Tris-HCl buffer (pH ¼ 7.4). The homogenate was centrifuged at 48,000 Â g (4 C) for 10 min and the supernatant decanted. The pellet was resuspended in 25 ml ice cold 50 mM TrisHCl buffer, and the homogenation and centrifugation repeated. The final pellet was resuspended in an appropriate volume ice cold 50 mM TrisHCl buffer to yield a concentration of 16 mg wet weight per ml, using a Polytron homogenizer for 10 sec. Protein concentrations were determined with the Bradford method (Bradford 1976) , using bovine serum albumin as standard and determining absorbance with a 96-well plate reader and a 560 nm filter (Labsystems Multiskan RC), where after the suspension was diluted with ice cold 50 mM Tris-HCl buffer to yield a protein concentration of 500 mg=ml. The membrane suspension was kept on ice until use.
Radioligand binding assays using membranes from rat brain
For the measurement of b-AR density, eight concentrations of [ 3 H]-propranolol ranging from 0.375 to 25 nM (in the final assay volume) were prepared in 50 mM Tris-HCl buffer (pH ¼ 7.4) and added in duplicate to membrane suspensions to yield a final assay volume of 1 ml to determine total binding. The same series, but also containing 60 mM propranolol, was used to define non-specific binding. After a 15 min incubation period in a shaking water bath at 25 C, the contents of the tubes were transferred to Whatman GF=B filters and rinsed twice with 5 ml ice cold 50 mM Tris-HCl buffer. The filters were placed in scintillation vials, scintillation cocktail added, and allowed to stand overnight where after radioactivity was counted.
Data analysis
Data from all studies with cultured cells were obtained from triplicate observations from at least 3 separate, comparable experiments, and results are expressed as average AE standard error of the mean (SEM). Semilogarithmic one-site competition-binding or dose-response curves were constructed as least square non-linear fits, utilizing the computer software GraphPad Prism (version 4.01 for Microsoft Windows, GraphPad Software, San Diego, CA, U.S.A.). The K i values were calculated from the IC 50 values of competition-binding curves, applying the K d value of the radioligand into the built-in Cheng-Prusoff correction of the software. Data from all FST studies with rats were from 3 separate, comparable experiments, each with 5 rats. For behavioural data (i.e. forced swim test) observations were made individually for each rat, while the tissue from indicated brain regions of 5 rats was pooled for membrane preparation for radioligand binding studies.
Sildenafil and antidepressant activity
Parallel locomotor control studies were routinely evaluated from 3 separate, comparable experiments, each with 2 rats (i.e. 2 additional rats added to each treatment group).
GraphPad Prism was also utilized for all statistical analyses of data. For comparison of two values, the unpaired Student's t-test (two-tailed) was implemented. For multiple comparisons the one-way ANOVA comparison was performed followed by either the Dunnett's post-test (for comparing experimental groups to the control) or the Tukey-Kramer post-test (for comparing experimental groups to each other). For all reported statistical probability values, p < 0.05 was regarded as statistically significant.
Results
Sildenafil pre-treatment potentiates muscarinic acetylcholine receptor signalling capacity Figure 1A depicts dose-response curves of the mAChR agonist methacholine (MeCh) in human neuroblastoma SH-SY5Y cells before and after a 24-h pre-treatment with 450 nM sildenafil, measuring inositol phosphates (IP x ) accumulation as response. It should be noted that these measurements were made after removal of sildenafil by means of thorough rinsing steps and at least 18 h incubation of the cells in radio-labeling medium, followed by additional washing steps (as described in the methods section above). The pEC 50 value of the dose-response curve of MeCh was unaltered by sildenafil pre-treatment (6.42 AE 0.29 for control vs. 6.03 AE 0.18 after sildenafil, not significantly different), while the E max increased approximately 3.4-fold relative to control from 61 AE 21% above basal for control to 205 AE 32% above basal after sildenafil (p < 0.001). In previous studies we have demonstrated that the pre-treatment of human neuroblastoma SH-SY5Y cells with certain drugs may change the cellular uptake of myo-[2-
3 H]inositol during the radio-labeling (as indicated by the total radioactivity of cells after the radio-labeling step), thereby potentially changing the response magnitude to MeCh (Brink et al. 2004 ). However, the pre-treatment with sildenafil did not alter the cellular uptake of myo-[2-3 H]-inositol during the radio-labeling (data not shown), so that this does not account for the observed increase in E max . Figure 1B depicts basal response versus E max values of MeCh in human neuroblastoma SH-SY5Y cells after a 24-h pre-treatment with 0, 100 or 450 nM sildenafil, respectively, measuring inositol phosphates (IP x ) accumulation as response. While the increase in the E max of MeCh after a pre-treatment with 450 nM sildenafil was already demonstrated in Fig. 1A , it can be seen here that pre-treatment with a lower concentration of 100 nM sildenafil also increases the E max of MeCh, here with a 4.2-fold increase from 61 AE 21% above basal to 260 AE 49% above basal (p< 0.01). The difference between the E max values after 100 and 450 nM sildenafil pre-treatments, respectively, was not statistically significant.
Laboratory validation of the forced swim test
A 15 min pre-exposure, as compared to no pre-exposure, of drug-naïve (vehicle treated control) rats to forced swimming 24 h before, increased immobility during the second (scoring) swim session from 100 AE 8.2% to 143 AE 7.1% (p ¼ 0.0005, data not presented graphically). In addition, 7 days fluoxetine-treated rats demonstrated significant values of the muscarinic acetylcholine receptor agonist methacholine in human neuroblastoma (SH-SY5Y) whole cells, 18 h after a 24-h pretreatment with 0, 100 or 450 nM sildenafil. Data are averages of at least triplicate measurements from three independent and comparable experiments and results were calculated as a percentage of control E max (i.e. after 0 nM sildenafil), expressed as mean AE SEM. Statistics: The data in A were analyzed using a unpaired Student's t-test (two-tailed) test where ÃÃÃ p < 0.001. The data in B were analyzed using a one-way ANOVA followed by a Dunnett post-test (i.e. vs. vehicle control) where Ã p < 0.05 and ÃÃ p < 0.01 120 C. B. Brink et al. anti-immobility effects compared to drug-naïve rats (64 AE 4.6% vs. 143 AE 7.1%, p< 0.001, data not presented graphically). The data therefore confirms that the forced swim test (FST), as outlined in the methodology and applied under our laboratory conditions, induced ''behavioural despair=significant immobility'' that was reversible after a chronic treatment program with fluoxetine. The FST therefore presents with sufficient sensitivity to detect the antidepressant-like actions of the positive control (the SSRI fluoxetine).
Sildenafil and antidepressant-like responses in rats
Forced swim test It is evident from the FST data presented in Fig. 2A that immobility is reduced significantly in fluoxetine-treated rats, as compared to vehicle-treated controls (100 AE 3.9% vs. 63.5 AE 5.4%, p < 0.01). However, immobility was not changed significantly compared to vehicle-treated controls in rats treated with either sildenafil alone (100 AE 3.9% vs. 93.8 AE 9.1%, p > 0.05) or atropine alone (100 AE 3.9% vs. 101.3 AE 3.8%, p> 0.05). Importantly, the sildenafil þ atropine combination did reduce immobility compared to vehicle control (100 AE 3.9% vs. 61.2 AE 4.8%, p < 0.01), while this reduction was comparable to that found with fluoxetine alone.
While the fluoxetine alone regime reduced immobility compared to the vehicle-treated control (as described above), the addition of sildenafil to fluoxetine (i.e. the fluoxetine þ sildenafil combination) did not cause any additional decrease in immobility over and above that observed with fluoxetine alone (63.5 AE 5.4% vs. 62.2 AE 4.0%). However, the addition of atropine to fluoxetine (i.e. the fluoxetine þ atropine combination) caused an additional decrease in immobility (63.5 AE 5.4% vs. 40.5 AE 1.3%, p < 0.05). Lastly, the addition of sildenafil to the fluoxetine þ atropine ropine regime (i.e. the fluoxetine þ atropine þ sildenafil triple combination) did not cause any additional decrease in immobility (40.5 AE 1.3% vs. 39.9 AE 2.5%, not significantly different). It is not clear from the data whether this lack of further increase in immobility by the triple combination may be due to a ceiling effect at about 40% immobility, or whether it truly represents no potentiation.
Locomotor activity
There were no significant alterations in locomotor activity (data not presented graphically) with any drug treatment regime compared to vehicle treated control, except for the fluoxetine þ sildenafil combination, where there was an increase in locomotor activity (100.0 AE 20.9% vs. 362.7 AE 112.5%, p< 0.05). This regime was not associated with any change in immobility ( Fig. 2A) and taken together, these results suggest that any reductions in immobility b-Adrenoceptor density Figure 2B depicts the b-AR concentration in the rat frontal cortex before and after treatment with the respective drug treatment regimes. As compared to the vehicle-treated control, the cortical b-AR concentration was decreased by fluoxetine alone (1409 AE 109.9 vs. 227.6 AE 59.97 fmol= mg protein, p< 0.01), unchanged by sildenafil alone (1409 AE 109.9 vs. 1140 AE 218.2 fmol=mg protein, not significantly different), decreased by fluoxetine þ sildenafil (1409 AE 109.9 vs. 411.1 AE 49.31 fmol=mg protein, p < 0.01), unchanged by atropine alone (1409 AE 109.9 vs. 1516 AE 486.1 fmol=mg protein, not significantly different), decreased by sildenafil þ atropine (1409 AE 109.9 vs. 534.8 AE 22.17 fmol=mg protein, p < 0.05), decreased by fluoxetine þ atropine (1409 AE 109.9 vs. 404.3 AE 59.5 fmol= mg protein, p< 0.01) and decreased by the triple combination of fluoxetine þ atropine þ sildenafil (1409 AE 109.9 vs. 514.1 AE 144.4 fmol=mg protein, p < 0.05). It can be noted from a direct comparison of Fig. 2A and B , that all treatment regimes that decreased immobility in the FST also downregulated b-ARs, and vice versa. These results therefore compliment the data from the FST, thereby confirming antidepressant-like action by the treatment regimes that reduced immobility on the FST (i.e. fluoxetine alone, fluoxetine þ sildenafil, fluoxetine þ atropine and sildenafil þ atropine þ sildenafil). The decrease in b-AR concentration did, however, not differ statistically significantly between the latter treatment groups.
Discussion
Sildenafil bolsters mAChR signalling capacity
The results depicted in Fig. 1 suggest that a 24-h pretreatment of human neuroblastoma SH-SY5Y cells with pharmacologically relevant high and low concentrations of sildenafil causes a dramatic increase in the signalling capacity of mAChRs (E max values increased approximately 3.4-to 4.2-fold), without altering the agonist potency (i.e. pEC 50 value unchanged). The current study has not investigated the mechanism underlying this phenomenon, which may, for example, include changes in mAChR concentration or bolstering of the neuronal mAChR signal-transduction system. However, previous studies using the same experimental protocol and cell line have demonstrated that high concentrations of either fluoxetine or imipramine (10 mM) reduces mAChR function and concentration (Brink et al. 2004) , while atropine alone does not alter mAChR function significantly (data not shown). This is directly opposite to the cholinotropic actions of sildenafil noted here and thus strongly implies opposing in vivo pharmacological responses between sildenafil and known antidepressants. Indeed, such an effect may be expected in the brain following increases in cerebral levels of cGMP, which is known to modulate the release of acetylcholine in various brain regions, including the striatum, hippocampus, nucleus accumbens, cortex (Ohkuma et al. 1995) and basal forebrain (see Prast and Philippu 2001) . NO-mediated cGMP synthesis, particularly in cortical areas (van Staveren et al. 2005) , is co-localized predominantly with the acetylcholine transporter or the neuronal glutamate transporter. Importantly, comparable levels of sildenafil have been noted in brain and peripheral tissue (Pagani et al. 2005) , while psychotropic effects have been reported during clinical use (Milman and Arnold 2002) , and in animals with the dosages used in this study (Ferrari et al. 2002; Prickaerts et al. 2002; Kurt et al. 2004; Harvey et al. 2005) , confirming that sildenafil has appreciable penetration into the brain.
According to the cholinergic supersensitivity hypothesis of depression, an increase in central cholinergic activity will be depressogenic (Janowsky et al. 1972) , with both mAChRs (Dilsaver 1986; Daws and Overstreet 1999; Chau et al. 2001 ) and nicotinic AChRs (Shytle et al. 2002) implicated as possible mediators of this response. Increased mAChR concentrations have been noted in the brain of suicide victims (Meyerson et al. 1982) , while neuroendocrine studies similarly suggest muscarinic receptor supersensitivity in depression (Fritze 1993) . Moreover, antimuscarinic drugs demonstrate efficacy in treatment resistant depression (Furey and Drevets 2006) . Consequently, the sildenafil-induced increase in mAChR signalling capacity, as observed in cultured human neuroblastoma cells, suggests that sildenafil-induced increases in cGMP and subsequent muscarinic-cholinergic activation may be depressogenic. Supporting this idea is that sildenafil has been found to counter the antidepressant-like responses evoked by the NMDA antagonist, memantine (Almeida et al. 2006) .
However, sildenafil effectively treats erectile dysfunction in men with depression and in men taking antidepressants, with no evidence that it worsens depressive symptoms (Tignol et al. 2004 ). Clearly, sildenafil may more compliment antidepressant treatment than oppose it. Indeed, clinical studies in depressed patients have noted a reduced number of NOS immunoreactive neurons in the hypothalamus (Bernstein et al. 1998) as well as reduced platelet NOS activity (Chrapko et al. 2006) , suggesting that raising NOcGMP activity would benefit the treatment of depression. Indeed, effective treatment of depression with the SRI paroxetine is associated with increased platelet NOS activity as well as elevation of the stable oxidative metabolites of NO (Chrapko et al. 2006) . Thus, despite evidence to the contrary in animal models (Harkin et al. 1999; Heiberg et al. 2002; Wegener et al. 2003; Harvey et al. 2006) , clinical studies would suggest that reduced NO activity (and hence by implication reduced cGMP) is causally linked to depression, and that strategies to reverse this would constitute successful treatment. Thus, while the in vitro data from neuroblastoma cells may argue in favour of a depressogenic action in vivo, the aforementioned clinical data prompted us to further investigate this question in an animal behavioural model. We therefore postulated that sildenafil may possess antidepressant activity driven by its inherent ability to selectively increase cGMP, but which is abrogated by a potentiation of muscarinic cholinergic activity. Considering that enhanced cholinergic drive adversely affects mood, and that sildenafil may positively modulate the cholinergic system (Devan et al. 2004; Patil et al. 2004) , an antidepressant-like response may be possible following the co-administration of sildenalfil with an antimuscarinic agent.
An antimuscarinic agent 'unmasks' an antidepressant-like action of sildenafil
Having established that the nominal onset of antidepressant activity with chronic fluoxetine treatment in the rat FST is 7 days, with no response after 3 days (data not shown), we noted that similar treatment with either atropine or sildenafil failed to evoke an antidepressant-like response ( Fig. 2A) . Important to note is that sildenafil alone displayed neither depressogenic nor antidepressant-like activity in the rat FST. However, the combination of sildenafil and atropine yielded an antidepressant-like response comparable to that observed with fluoxetine alone (Fig. 2A) .
Although not believed to contribute directly to the moodelevating effects of antidepressant treatments (SuranyiCadotte et al. 1985; Baldessarini 2006 ), a useful neuropharmacological marker for antidepressant action is a reduction in cortical b-adrenoceptor density (Sethy et al. 1988; Stahl 1996) . As with onset of action, this requires chronic dosing to occur. In the current study, the antidepressant-like response in the FST following fluoxetine and following the sildenafil þ atropine combination was corroborated by a significant decrease in cortical b-AR concentration (Fig. 2B) . However, both atropine and sildenafil alone were devoid of antidepressant-like effects in the FST and effects on b-AR concentration ( Fig. 2A and B) .
Although anticholinergic agents are generally disregarded as clinically effective antidepressants (Fritze 1993; Gillin et al. 1995) , their efficacy in treating resistant depression (Furey and Drevets 2006) emphasizes that disturbances in cholinergic activity play a distinct yet unresolved role in the neurobiology of depression. Indeed, while atropine alone had no effect on swim stress-evoked immobility, it bolstered the antidepressant-like activity of fluoxetine, as evinced by a further reduction in immobility in the FST ( Fig. 2A) , although reduced b-AR concentration was sustained but not further increased (Fig. 2) . A similar response was noted for the fluoxetine, atropine and sildenafil combination vs. fluoxetine. The latter observations are not unusual, given that antidepressant efficacy and decreased cortical b-AR concentration are not necessarily correlated or causally related (Suranyi-Cadotte et al. 1985; Baldessarini 2006) , with b-AR density used primarily as a neuroplastic marker of antidepressant effects. We have previously demonstrated that fluoxetine causes a significant reduction in muscarinic receptor function and concentration in neuroblastoma cells (Brink et al. 2004 ) and it would therefore be expected that fluoxetine will similarly suppress muscarinic cholinergic activity in vivo, supportive of the cholinergic hypothesis of depression (Janowsky et al. 1972 ). This hypothesis may also explain why the addition of an antimuscarinic agent would potentiate the antidepressant-like action of fluoxetine.
However, unlike fluoxetine that may attenuate cholinergic drive in addition to its more established effects on synaptic monoamine levels, the cholinotropic actions of sildenafil may preclude it from such a more robust antidepressant response. Together our data strongly support the hypothesis that sildenafil may possess antidepressant-like activity, but that is only revealed after attenuation of central muscarinic cholinergic activity. Since atropine failed to have antidepressant effects on its own, the antidepressant effects of the latter combination may involve sildenafil's ability to increase cGMP and prompts further investigation.
Sildenafil does not reverse the antidepressant-like effect of fluoxetine According to earlier pre-clinical studies that have described the antidepressant effects manifest by inhibition of NO and=or cGMP (Eroglu and Caglayan 1997; Wegener et al. 2003) , as well as the anxiogenic effects of sildenafil Kurt et al. 2004) , what is intriguing in the current data is that, while sildenafil failed to evoke a Sildenafil and antidepressant activity noted antidepressant effect, it did not reverse the antidepressant effects of fluoxetine in the FST or on b-AR density. Because of its bolstering action on cGMP, a possible reversal of the effects of fluoxetine, as has been described with memantine (Almeida et al. 2006) , would have been a reasonable expectation and in keeping with the earlier animal data. This suggests that sildenafil's lack of antidepressant actions lies less with its ability to increase cGMP and more with its cholinotropic actions. It has been suggested that muscarinic receptors in the nucleus accumbens control immobility in the FST, with the onset of immobility dependent on the activation of post-synaptic M 1 mAChRs (Chau et al. 2001) , and that would be prevented by a centrally acting antimuscarinic agent such as atropine.
Conclusions
The current study provides strong support for the hypothesis that sildenafil may posses antidepressant activity, but which is attenuated or lost due to its ability to increase mAChR signalling capacity. This antidepressant activity may be attributed to increased cGMP, suggesting a possible complex interaction between the cholinergic and NOcGMP pathways in the regulation of mood. The mechanism mediating the cholinotropic action of sildenafil, whether it is secondary to PDE5 inhibition, or due to another action of sildenafil needs further investigation. A dose-response relationship for the antidepressant-like effect of sildenafil and time to onset of action also needs further exploration. In addition, it would be imperative to investigate whether sildenafil will display additive antidepressant activity when combined with antidepressants possessing antimuscarinic activity, such as the tricyclic antidepressants.
